JCR Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

JCR Pharmaceuticals CEO'su Shin Ashida, Jun2005 tarihinde atandı, in görev süresi 19.42 yıldır. şirketin hisselerinin 0.009% doğrudan sahiptir ve bu hisselerin değeri $ 51.46K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.4 yıl ve 4.8 yıldır.

Anahtar bilgiler

Shin Ashida

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	19.4yrs
CEO sahipliği	0.009%
Yönetim ortalama görev süresi	6.4yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Shin Ashida (81 yo)

19.4yrs

Görev süresi

Mr. Shin Ashida has been the Chairman of JCR Pharmaceuticals Co., Ltd. since July 1995 and its Chief Executive Officer since June 2005. Mr. Ashida has been the President and Chief Operating Officer of JCR...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shin Ashida	Chairman	19.4yrs	Veri yok	0.0085% $ 51.5k
Yoshihiro Ota	Director of Accounting Department & Corporate Strategy Department (Finance)	no data	Veri yok	Veri yok
Yutaka Honda	Sr. Exec. Offi. of Admin.	8.4yrs	Veri yok	Veri yok
Hiroyuki Fukuya	Director of Legal Affairs Department - Administration Division	no data	Veri yok	Veri yok
Toru Ashida	Director	4.6yrs	Veri yok	0.22% $ 1.3m
Ryutaro Makino	Director of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div.	4.1yrs	Veri yok	Veri yok
Katsuya Nishino	Executive Vice President	14.3yrs	Veri yok	Veri yok
Hiroshi Yoshimoto	Senior Advisor	13.5yrs	Veri yok	Veri yok
Takayo Egawa	Senior Executive Officer & Director of International Affairs	no data	Veri yok	Veri yok
Toshihiro Ishikiriyama	Senior Managing Executive Officer & Executive Director of Business Development Division	less than a year	Veri yok	0.0066% $ 39.6k
Hiroyuki Sonoda	Senior Managing Executive Officer of Research	6.4yrs	Veri yok	0.0019% $ 11.6k
Junichi Ando	Managing Executive Officer of Production & Executive Director of Production Division	3.4yrs	Veri yok	Veri yok

6.4yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim: JCRR.F 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shin Ashida	Chairman	19.4yrs	Veri yok	0.0085% $ 51.5k
Toru Ashida	Director	no data	Veri yok	0.22% $ 1.3m
Hiroyuki Sonoda	Senior Managing Executive Officer of Research	4.8yrs	Veri yok	0.0019% $ 11.6k
Yoshio Hiyama	Director	3.4yrs	Veri yok	0.0021% $ 12.8k
Andrea Spezzi	Director & Managing Executive Officer of Development Division	less than a year	Veri yok	Veri yok
Marc Dunoyer	Independent Outside Director	1.4yrs	Veri yok	Veri yok
Kazuhiko Yamada	Outside Audit & Supervisory Board Member	18.4yrs	Veri yok	0.010% $ 63.0k
Philippe Fauchet	Independent Outside Director	2.4yrs	Veri yok	Veri yok
Toshihide Yoda	Independent Outside Director	6.4yrs	Veri yok	Veri yok
Yutaka Atomi	Independent Outside Director	2.4yrs	Veri yok	Veri yok
Takashi Suetsuna	Independent Outside Director	7.4yrs	Veri yok	Veri yok
Yuko Hayashi	Independent Outside Director	6.4yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

65.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: JCRR.F 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

JCR Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Appoints Yoh Ito as Senior Corporate Officer

JCR Pharmaceuticals Co., Ltd. Announces Executive Changes

Recent updates

JCR Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIA

JCR Pharmaceuticals Co., Ltd. Announces Interim Dividend

JCR Pharmaceuticals Co., Ltd. Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual Congress

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

JCR Pharmaceuticals Co., Ltd Announces Discontinuation of TEMCELL HS Inj. Expanded Indication Development for Neonatal Hypoxic Ischemic Encephalopathy

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024

JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion

JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index (USD)

JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

JCR Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Jan 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA

JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)

PHC IVD and JCR Announce GROWJECTOR® Duo

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Oct 25, 2023

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

JCR Receives Approval to Start Global Phase I/II Clinical Trial for JR-441 for the Treatment of Mucopolysaccharidosis Type III A (MPS IIIA)

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Receives an Approval for Expanded Indication of Growject®? in Short Stature Due to SHOX-Deficiency

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Jul 26, 2023

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

JCR Pharmaceuticals Co., Ltd. to Present Phase I/II Clinical Data on JR-171

U.S. Fda Grants Rare Pediatric Disease Designation for JCR Pharmaceuticals Co., Ltd. Jr-141 for Mpsii

JCR Pharmaceuticals Co., Ltd. Appoints Yoh Ito as Senior Corporate Officer

JCR Pharmaceuticals Announces Interim Dividend Payable on December 9, 2022; Provided Dividend Guidance for Fiscal 2023

JCR to Initiate Development of New Drug Candidate for Fucosidosis

JCR Pharmaceuticals Co., Ltd. Announces Interim Dividend on Retained Earnings, Payable on December 9, 2022

Jcr Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

JCR Pharmaceuticals Co., Ltd. Announces Update on Application for Manufacturing and Marketing Approval of JR-141 for Treatment of MPS II (Hunter Syndrome) in Brazil

JCR Pharmaceuticals Co., Ltd Files for Expanded Use GROWJECT for Short Stature Due to SHOX-Deficiency

JCR Pharmaceuticals Co., Ltd. Announces Executive Changes

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş